2,226
Views
12
CrossRef citations to date
0
Altmetric
Research Paper

Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea

, , , , , & ORCID Icon show all
Pages 1136-1142 | Received 18 May 2017, Accepted 01 Aug 2017, Published online: 31 Aug 2017

References

  • World Health Organization (WHO). WHO global report on trends in prevalence of tobacco smoking 2015. Geneva, Switzerland; WHO; 2015.
  • Hecht SS, Stepanov I, Carmella SG. Exposure and metabolic activation biomarkers of carcinogenic tobacco-specific nitrosamines. Acc Chem Res 2016;49:106–14.
  • Su T, Bao Z, Zhang QY, et al. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 2000;60:5074–9.
  • Jalas J, Hecht S, Murphy S. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005;18:95–110.
  • Megaraj V, Zhou X, Xie F, et al. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model. Carcinogenesis 2014;35:131–7.
  • Kubota T, Nakajima-Taniguchi C, Fukuda T, et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 2006;6:115–9.
  • Wang H, Tan W, Hao B, et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003;63:8057–61.
  • Rossini A, Simao TA, Albano RM, Pinto LFR. CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008;9:1737–52.
  • Timofeeva M, Kropp S, Sauter W, et al. CYP 450 polymorphisms as risk factors for early onset lung cancer: gender specific differences. Carcinogenesis 2009;30:1161–9.
  • Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000;68:35–43.
  • Prasopthum A, Pouyfung P, Sarapusit S, et al. Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence. Drug Metab Pharmacokinet 2015;30:174–81.
  • Dogra NK, Kumar S. A review on ethno-medicinal uses and pharmacology of Vernonia cinerea less. Nat Prod Res 2015;29:1102–17.
  • Wongwiwatthananukit S, Benjanakaskul P, Songsak T, et al. Efficacy of Vernonia cinerea for smoking cessation. J Health Res 2009;23:31–6.
  • Pratheeshkumar P, Kuttan G. Vernonia cinerea Less. inhibits tumor cell invasion and pulmonary metastasis in C57BL/6 mice. Integr Cancer Ther 2011;10:178–91.
  • Cho JJ, Cho CL, Kao CL, et al. Crude aqueous extracts of Pluchea indica (L.) Less. inhibit proliferation and migration of cancer cells through induction of p53-dependent cell death. BMC Complement Altern Med 2012;12:265.
  • Buapool D, Mongkol N, Chantimal J, et al. Molecular mechanism of anti-inflammatory activity of Pluchea indica leaves in macrophages RAW 264.7 and its action in animal models ofinflammation. J Ethnopharmacol 2013;146:495–504.
  • Hussain H, Al-Harrasi A, Abbas G, et al. The genus Pluchea: phytochemistry, traditional uses, and biological activities. Chem Biodivers 2013;10:1944–71.
  • Chakravarty MS. New thiophene derivatives from Pluchea indica. Indian J Chem 1994;33:978–80.
  • Qiu YQ, Qi SH, Zhang S, et al. Thiophene derivatives from the aerial part of Pluchea indica. Heterocycles 2008;75:1757–64.
  • Pouyfung P, Prasopthum A, Sarapusit S, et al. Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents. Drug Metab Pharmacokinet 2014;29:75–82.
  • Shimada T, Kim D, Murayama N, et al. Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. Chem Res Toxicol 2013;26:517.
  • Gramec D, Peterlin Mašič L, Sollner Dolenc M, Bioactivation potential of thiophene-containing drugs. Chem Res Toxicol 2014;27:1344–58.
  • Foroozesh M, Primrose G, Guo Z, et al. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem Res Toxicol 1997;10:91–102.
  • Smith BD, Sanders JL, Porubsky PR, et al. Structure of the human lung cytochrome P450 2A13. J Biol Chem 2007;282:17306–13.
  • Yoo HH, Lee MW, Kim YC, et al. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas. Drug Metab Dispos 2007;35:1759–65.
  • Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 2008;324:992–9.
  • von Weymarn LB, Chun JA, Knudsen GA, Hollenberg PF. Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. Chem Res Toxicol 2007;20:1252–9.
  • Dhouib H, Jallouli M, Draief M, et al. Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol. Pathol Biol 2015;63:258–67.